Chronic viral infections caused by the Epstein-Barr virus (EBV), cytomegalovirus (CMV), human herpesvirus 7 (HHV7), and herpesvirus 8 (HHV8) increase the risk of idiopathic pulmonary fibrosis (IPF), but not of acute flares that mark disease worsening, according to data from a meta-analysis study. The study,…
News
A metabolic process called the mevalonate pathway may be a promising therapeutic target to fight idiopathic pulmonary fibrosis (IPF), according to an early research study using mouse models and lung fluid collected from IPF patients. Researchers also suggest that lung injury may not be as key…
Rare disease-themed videos glowed on a large screen before an audience of people in wheelchairs, with crutches, and bearing oxygen tanks this Nov. 9 and 10 in San Francisco. Disorder: The Rare Disease Film Festival strives to eventually host a film about every one of the nearly 7,000 rare…
Indalo Therapeutics’ lead investigational anti-fibrotic candidate, IDL-2965, is safe and shows favorable pharmacokinetics (absorption, distribution, and elimination in the body) in healthy people, according to interim results of a Phase 1/2a clinical trial. The results were presented at the Pulmonary Fibrosis Foundation (PFF) Summit, held Nov. 7–9 in…
Exposure to dust in the workplace for 10 years or longer seems to have no detrimental effect on the response of patients with idiopathic pulmonary fibrosis (IPF) to anti-fibrotic treatment with Esbriet (pirfenidone) or Ofev (nintedanib), a study has found. The study “Antifibrotic treatment response and…
Ofev (nintedanib) slows the rate of decline in lung function in people with interstitial lung diseases (ILDs) associated with autoimmune diseases, a new analysis of data from a Phase 3 clinical trial suggests. Ofev is an anti-fibrotic therapy — a medication that lessens tissue scarring — that is already…
CrystecPharma signed a letter of understanding with Iconovo to develop innovative dry powder inhaler solutions for the treatment of patients with lung diseases, including pulmonary fibrosis. Direct delivery of medications into the lungs permits their rapid uptake via a non-invasive route. The two key factors that determine successful…
The Pulmonary Fibrosis Foundation (PFF) announced a research initiative that aims to expand precision medicine strategies for diagnosing and treating idiopathic pulmonary fibrosis (IPF). The study, called PRECISIONS (for Prospective tReatment EffiCacy in IPF uSIng genOtype for Nac Selection), is being funded by a $22 million grant from the National Institutes of Health and …
Treatment with the approved therapy Esbriet (pirfenidone), marketed by Genentech, helps preserve lung function in people with idiopathic pulmonary fibrosis (IPF), real-world data from the PROOF registry show. The results were reported in “Longitudinal clinical outcomes in a real-world population of patients with idiopathic…
Investigational therapy AD-214 raised no safety concerns in preliminary studies in non-human primates, and AdAlta, the therapy’s developer, is now planning to launch a Phase 1 clinical trial in humans, the company announced. AD-214 is a modification of AdAlta’s original lead candidate for the treatment of pulmonary fibrosis…
